Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide and Dexamethasone in Anti-MAG Neuropathy
NCT03701711Phase 1Terminated
- Sponsor
- The Ohio State University
- Start
- Sep 2018
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lenalidomide in anti-myelin-associated glycoprotein neuropathy, sponsored by The Ohio State University. Primary endpoint: Maximum Tolerated Dose up to 24 months. Started Sep 2018; status: terminated.
02
Drugs
lenalidomide
03
Conditions
anti-myelin-associated glycoprotein neuropathy
Beyond the preview
Go deeper on NCT03701711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03701711.